FI3921033T3 - Arginaasiestäjiä ja menetelmiä niiden käyttämiseksi - Google Patents

Arginaasiestäjiä ja menetelmiä niiden käyttämiseksi Download PDF

Info

Publication number
FI3921033T3
FI3921033T3 FIEP20709706.4T FI20709706T FI3921033T3 FI 3921033 T3 FI3921033 T3 FI 3921033T3 FI 20709706 T FI20709706 T FI 20709706T FI 3921033 T3 FI3921033 T3 FI 3921033T3
Authority
FI
Finland
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
formula
alkyl
Prior art date
Application number
FIEP20709706.4T
Other languages
English (en)
Finnish (fi)
Inventor
Scott Nathan Mlynarski
Tyler Grebe
Sameer Kawatkar
Maurice Raymond Verschoyle Finlay
Iain Simpson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of FI3921033T3 publication Critical patent/FI3921033T3/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FIEP20709706.4T 2019-02-08 2020-02-07 Arginaasiestäjiä ja menetelmiä niiden käyttämiseksi FI3921033T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962802765P 2019-02-08 2019-02-08
PCT/IB2020/050982 WO2020161675A1 (en) 2019-02-08 2020-02-07 Arginase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
FI3921033T3 true FI3921033T3 (fi) 2023-09-15

Family

ID=69770954

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20709706.4T FI3921033T3 (fi) 2019-02-08 2020-02-07 Arginaasiestäjiä ja menetelmiä niiden käyttämiseksi

Country Status (33)

Country Link
US (2) US12435097B2 (https=)
EP (1) EP3921033B1 (https=)
JP (1) JP7526734B2 (https=)
KR (1) KR102759971B1 (https=)
CN (1) CN113395996B (https=)
AU (1) AU2020218651B2 (https=)
BR (1) BR112021015581A2 (https=)
CA (1) CA3127755A1 (https=)
CL (1) CL2021002056A1 (https=)
CO (1) CO2021011039A2 (https=)
CR (1) CR20210463A (https=)
DK (1) DK3921033T3 (https=)
DO (2) DOP2021000166A (https=)
EA (1) EA202192114A1 (https=)
ES (1) ES2960034T3 (https=)
FI (1) FI3921033T3 (https=)
HR (1) HRP20231092T1 (https=)
HU (1) HUE062968T2 (https=)
IL (1) IL285108B2 (https=)
LT (1) LT3921033T (https=)
MA (1) MA56324B1 (https=)
MX (1) MX2021009499A (https=)
MY (1) MY206577A (https=)
PE (1) PE20220280A1 (https=)
PH (1) PH12021551902A1 (https=)
PL (1) PL3921033T3 (https=)
PT (1) PT3921033T (https=)
RS (1) RS64781B1 (https=)
SG (1) SG11202108503PA (https=)
SI (1) SI3921033T1 (https=)
SM (1) SMT202300337T1 (https=)
WO (1) WO2020161675A1 (https=)
ZA (1) ZA202105833B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117186134A (zh) * 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (sv) 1999-05-03 1999-05-03 Astra Ab New compounds
SE0300907D0 (sv) 2003-03-31 2003-03-31 Astrazeneca Ab Novel compounds
LT2389352T (lt) 2009-01-26 2019-06-10 The Trustees Of The University Of Pennsylvania Arginazės inhibitoriai ir naudojimo būdai
SG10201503168VA (en) * 2010-04-22 2015-06-29 Mars Inc Inhibitors of arginase and their therapeutic applications
HRP20160305T1 (hr) 2010-10-26 2016-07-01 Mars, Incorporated Borati kao inhibitori arginaze
WO2013059437A1 (en) 2011-10-19 2013-04-25 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
RU2018138195A (ru) * 2012-12-17 2018-12-18 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US10143699B2 (en) * 2015-06-23 2018-12-04 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
WO2017175185A1 (en) 2016-04-08 2017-10-12 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
CN114989205A (zh) 2016-12-22 2022-09-02 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
CN108794517B (zh) 2017-04-27 2021-03-30 南京谷睿生物科技有限公司 一种精氨酸酶抑制剂及其制备方法与用途
CN117186134A (zh) * 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
EP3765006A4 (en) * 2018-03-13 2022-02-23 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
CN111770756B (zh) 2018-04-27 2023-03-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
MA53427B1 (fr) * 2018-08-22 2024-06-28 Astrazeneca Ab Inhibiteurs de l'arginase et leurs méthodes d'utilisation

Also Published As

Publication number Publication date
DOP2024000181A (es) 2024-10-15
BR112021015581A2 (pt) 2021-10-05
CN113395996A (zh) 2021-09-14
HUE062968T2 (hu) 2023-12-28
EP3921033A1 (en) 2021-12-15
CO2021011039A2 (es) 2021-09-09
SMT202300337T1 (it) 2023-11-13
JP7526734B2 (ja) 2024-08-01
PT3921033T (pt) 2023-10-11
US20250282800A1 (en) 2025-09-11
IL285108A (en) 2021-09-30
KR102759971B1 (ko) 2025-01-23
ZA202105833B (en) 2025-03-26
MA56324B1 (fr) 2023-10-31
IL285108B1 (en) 2024-06-01
PL3921033T3 (pl) 2024-01-15
DK3921033T3 (da) 2023-10-16
DOP2021000166A (es) 2021-09-30
MX2021009499A (es) 2021-09-08
JP2022521474A (ja) 2022-04-08
PE20220280A1 (es) 2022-02-25
SI3921033T1 (sl) 2023-11-30
IL285108B2 (en) 2024-10-01
CR20210463A (es) 2021-10-15
SG11202108503PA (en) 2021-09-29
WO2020161675A1 (en) 2020-08-13
ES2960034T3 (es) 2024-02-29
RS64781B1 (sr) 2023-11-30
CL2021002056A1 (es) 2022-03-04
KR20210126044A (ko) 2021-10-19
PH12021551902A1 (en) 2022-08-01
US12435097B2 (en) 2025-10-07
AU2020218651B2 (en) 2023-01-12
US20220106335A1 (en) 2022-04-07
LT3921033T (lt) 2023-09-25
CA3127755A1 (en) 2020-08-13
EA202192114A1 (ru) 2021-12-01
EP3921033B1 (en) 2023-07-26
AU2020218651A1 (en) 2021-09-30
CN113395996B (zh) 2024-05-28
MY206577A (en) 2024-12-24
HRP20231092T1 (hr) 2023-12-22

Similar Documents

Publication Publication Date Title
HRP20201984T1 (hr) Priprema (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
JP2019514874A5 (https=)
IL275762B2 (en) History of PHENYL-SO2-NH-C(=O)-PHENYL-PIPERAZINE-CH2-1,2-CYCLOHEXANE-BICYCLO[1.1.1]PENTANE and spirit preparations containing them
JOP20210001A1 (ar) مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2
CR20200418A (es) Inhibidores de orginasa y sus mètodos de uso antecedentes
OA12697A (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.
FI4360713T3 (fi) Kinatsoliinijohdannaisia kasvaimia estävinä aineina
FI3921033T3 (fi) Arginaasiestäjiä ja menetelmiä niiden käyttämiseksi
JP2010511626A5 (https=)
HRP20161428T1 (hr) Modulatori farmakokinetičkih svojstava lijekova
FI4019019T3 (fi) Rilutsolin, rilutsolin aihiolääkkeiden tai rilutsolin analogien käyttö immunoterapioiden kanssa syövän hoidossa
WO2010055304A3 (en) Oxazole or imidazole derivatives for use in the treatment of autoimmune disesases, in particular multiple sclerosis
JP2013532652A5 (https=)
RU2400483C2 (ru) Пуриновые производные в качестве агонистов рецептора a2a
JP2016518434A5 (https=)
WO2007146124A3 (en) Deuterated tadalafil derivatives
JP2019532092A5 (https=)
RU2403253C2 (ru) Пуриновые производные для применения в качестве агонистов аденозинового рецептора а-2а
PH12017502388A1 (en) 1,4-di-substituted imidazole derivative
JP2019527724A5 (https=)
CA2728098A1 (en) Pyrazole-containing tricyclic compounds as_antagonits of an ep1 receptor
RU2013136895A (ru) Новое бициклическое соединение или его соль
JP2018535261A5 (https=)
JP2018504411A5 (https=)
AR055133A1 (es) Inhibidores de la p38- map - quinasa para el uso de los mismos